Compare LUNG & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | BEAT |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Industrial Specialties | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 53.2M |
| IPO Year | 2020 | N/A |
| Metric | LUNG | BEAT |
|---|---|---|
| Price | $1.35 | $0.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $5.38 | ★ $5.63 |
| AVG Volume (30 Days) | 349.1K | ★ 553.7K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,497,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $18.46 | $315.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $0.54 |
| 52 Week High | $3.88 | $4.00 |
| Indicator | LUNG | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 32.53 |
| Support Level | $1.20 | $0.54 |
| Resistance Level | $1.45 | $0.94 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 32.14 | 4.27 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.